Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the α-adrenergic receptor antagonist

References

• Issa MM, Regan TS. Medical therapy for benign prostatic hyperplasia–present and future impact. Am J Manag Care. 2007;13:S4–S9.
   PubMed Web of Science ®Google Scholar
• Ziada A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: an overview. Urology. 1999;53:1–6.
   PubMed Web of Science ®Google Scholar
• Barry MJ. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology. 2001;58:25–32; discussion 32.
   PubMed Web of Science ®Google Scholar
• Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology. 2002;59:245–250.
   PubMed Web of Science ®Google Scholar
• Girman CJ, Jacobsen SJ, Tsukamoto T, et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology. 1998;51:428–436.
   PubMed Web of Science ®Google Scholar
• Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403–415.
   PubMed Web of Science ®Google Scholar
• Park SG, Yeo JK, Cho DY, et al. Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasia. Aging Male. 2017 DOI:10.1080/13685538.2017.1311857
   PubMed Web of Science ®Google Scholar
• Besiroglu H, Dursun M, Otunctemur A, et al. The association between triglyceride high density lipoprotein cholesterol ratio and benign prostate hyperplasia in non-diabetic patients: a cross-sectional study. Aging Male. 2017;23:1–7.
   Web of Science ®Google Scholar
• Asiedu B, Anang Y, Nyarko A, et al. The role of sex steroid hormones in benign prostatic hyperplasia. Aging Male. 2017;20:17–22.
   PubMed Web of Science ®Google Scholar
• Girman CJ. Natural history and epidemiology of benign prostatic hyperplasia: relationship among urologic measures. Urology. 1998;51:8–12.
   PubMed Web of Science ®Google Scholar
• Girman CJ, Epstein RS, Jacobsen SJ, et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology. 1994;44:825–831.
   PubMed Web of Science ®Google Scholar
• Girman CJ, Jacobsen SJ, Guess HA, et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol. 1995;153:1510–1515.
   PubMed Web of Science ®Google Scholar
• Girman CJ, Jacobsen SJ, Rhodes T, et al. Association of health-related quality of life and benign prostatic enlargement. Eur Urol. 1999;35:277–284.
   PubMed Web of Science ®Google Scholar
• Mochtar CA, Laan W, Van Houwelingen KP, et al. Polymorphisms in the alpha1A-adrenoceptor gene do not modify the short- and long-term efficacy of alpha1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. BJU Int. 2006;97:852–855.
   PubMed Web of Science ®Google Scholar
• McVary KT, Razzaq A, Lee C, et al. Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod. 1994;51:99–107.
   PubMed Web of Science ®Google Scholar
• Boesch ST, Corvin S, Zhang J, et al. Modulation of the differentiation status of cultured prostatic smooth muscle cells by an α1-adrenergic receptor antagonist. Prostate. 1999;39:226–233.
   PubMed Web of Science ®Google Scholar
• Qian X, Yu G, Qian Y, et al. Efficacy of 5α-reductase inhibitors for patients with large benign prostatic hyperplasia (>80 mL) after transurethral resection of the prostate. Aging Male. 2015;18:238–243.
   PubMed Web of Science ®Google Scholar
• Price D. Potential mechanisms of action of superselective α(1)-adrenoceptor antagonists. Eur Urol. 2001;40:5–11.
   PubMed Web of Science ®Google Scholar
• Civantos Calzada B, Aleixandre de Artinano A. α-adrenoceptor subtypes. Pharmacol Res. 2001;44:195–208.
   PubMed Web of Science ®Google Scholar
• Nasu K, Moriyama N, Kawabe K, et al. Quantification and distribution of α1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol. 1996;119:797–803.
   PubMed Web of Science ®Google Scholar
• Malloy BJ, Price DT, Price RR, et al. α1-adrenergic receptor subtypes in human detrusor. J Urol. 1998;160:937–943.
   PubMed Web of Science ®Google Scholar
• Ko WJ, Han HH, Ham WS, et al. Daily use of sildenafil 50mg at night effectively ameliorates nocturia in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: an exploratory multicenter, double-blind, randomized, placebo-controlled study. Aging Male. 2017;20:81–88.
   PubMed Web of Science ®Google Scholar
• Pajovic B, Radojevic N, Dimitrovski A, et al. The therapeutic potential of royal jelly in benign prostatic hyperplasia. Comparison with contemporary literature. Aging Male. 2016;19:192–196.
   PubMed Web of Science ®Google Scholar
• Meuleman EJ, Legros JJ, Bouloux PM, et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male. 2015;18:157–163.
   PubMed Web of Science ®Google Scholar
• Favilla V, Russo GI, Privitera S, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. Aging Male. 2016;19:175–181.
   PubMed Web of Science ®Google Scholar
• Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–575.
   PubMed Web of Science ®Google Scholar
• Barry MJ, Fowler FJ, Bin L, et al. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol. 1997;157:10–14; discussion 14–15.
   PubMed Web of Science ®Google Scholar
• Stroup SP, Palazzi-Churas K, Kopp RP, et al. Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. BJU Int. 2012;109:84–87.
   PubMed Web of Science ®Google Scholar
• McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–2398.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Lee JY, Meehan AG, et al. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol. 2011;185:1369–1373.
   PubMed Web of Science ®Google Scholar
• Berges R, Gsur A, Feik E, et al. Association of polymorphisms in CYP19A1 and CYP3A4 genes with lower urinary tract symptoms, prostate volume, uroflow and PSA in a population-based sample. World J Urol. 2011;29:143–148.
   PubMed Web of Science ®Google Scholar
• Dai F, Lin X, Chang C, et al. Nuclear export of Smad2 and Smad3 by RanBP3 facilitates termination of TGF-β signaling. Dev Cell. 2009;16:345–357.
   PubMed Web of Science ®Google Scholar
• Bontemps Y, Vuillermoz B, Antonicelli F, et al. Specific protein-1 is a universal regulator of UDP-glucose dehydrogenase expression: its positive involvement in transforming growth factor-β signaling and inhibition in hypoxia. J Biol Chem. 2003;278:21566–21575.
   PubMed Web of Science ®Google Scholar
• Foglar R, Shibata K, Horie K, et al. Use of recombinant α 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol. 1995;288:201–207.
   PubMed Web of Science ®Google Scholar
• Wilt TJ, MacDonald R, Nelson D. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. J Urol. 2002;167:177–183.
   PubMed Web of Science ®Google Scholar
• Kim J, Yanagihara Y, Kikugawa T, et al. A signaling network in phenylephrine-induced benign prostatic hyperplasia. Endocrinology. 2009;150:3576–3583.
   PubMed Web of Science ®Google Scholar
• Mononen N, Schleutker J. Polymorphisms in genes involved in androgen pathways as risk factors for prostate cancer. J Urol. 2009;181:1541–1549.
   PubMed Web of Science ®Google Scholar
• Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit. 2004;26:192–199.
   PubMed Web of Science ®Google Scholar
• Gsur A, Feik E, Madersbacher S. Genetic polymorphisms and prostate cancer risk. World J Urol. 2004;21:414–423.
   PubMed Web of Science ®Google Scholar
• Tayeb MT, Clark C, Sharp L, et al. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep. 2002;9:653–655.
   PubMed Web of Science ®Google Scholar
• Alcaraz A, Hammerer P, Tubaro A, et al. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol. 2009;55:864–873.
   PubMed Web of Science ®Google Scholar
• Sciarra A, Di Silverio F, Salciccia S, et al. Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol. 2007;52:964–972.
   PubMed Web of Science ®Google Scholar
• De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011;60:106–117.
   PubMed Web of Science ®Google Scholar
• Arivazhagan J, Nandeesha H, Dorairajan LN, et al. Association of elevated interleukin-17 and angiopoietin-2 with prostate size in benign prostatic hyperplasia. Aging Male. 2017;20:115–118.
   PubMed Web of Science ®Google Scholar
• Fwu CW, Eggers PW, Kaplan SA, et al. Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. J Urol. 2013;190:187–193.
   PubMed Web of Science ®Google Scholar
• Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol. 2008;53:1228–1235.
   PubMed Web of Science ®Google Scholar